Skip to main content
Erschienen in: Abdominal Radiology 2/2018

19.10.2017

Irreversible electroporation of pancreatic adenocarcinoma: a primer for the radiologist

verfasst von: M. Farzan Rashid, Elizabeth M. Hecht, Jonathan A. Steinman, Michael D. Kluger

Erschienen in: Abdominal Radiology | Ausgabe 2/2018

Einloggen, um Zugang zu erhalten

Abstract

Irreversible electroporation (IRE) is increasingly used for the ablation of unresectable locally advanced pancreatic adenocarcinoma. Unlike other ablation technologies that cannot be safely used around critical vasculature or ducts for risk of thermal damage, IRE uses high-voltage pulses to disrupt cellular membranes. This causes cell death by apoptosis and inflammation. IRE has been deployed by both open and percutaneous approaches. Generator parameters are the same for both approaches, and settings are pancreas specific. Variations in settings, probe placement, and probe exposure can result in thermal damage or reversible electroporation and resultant treatment failure, morbidity, or mortality. When used properly, IRE appears to improve overall survival and local recurrence, but does not influence the rate of distant recurrence. However, studies of both open and percutaneous approaches have been relatively small, non-controlled, and without appropriate comparisons. It is challenging for the radiologist to interpret treatment effects after IRE because of a dearth of guiding literature and pathologic correlates. This primer describes technical aspects, pathology correlates, post-IRE imaging, and outcomes for percutaneous and open approaches.
Literatur
1.
Zurück zum Zitat Hammel P, Huguet F, van Laethem JL, et al. (2016) Effect of chemoradiotherapy vs. chemotherapy on survival in patients with locally advanced pancreatic cancer controlled after 4 months of gemcitabine with or without erlotinib: the LAP07 randomized clinical trial. JAMA 315:1844–1853CrossRefPubMed Hammel P, Huguet F, van Laethem JL, et al. (2016) Effect of chemoradiotherapy vs. chemotherapy on survival in patients with locally advanced pancreatic cancer controlled after 4 months of gemcitabine with or without erlotinib: the LAP07 randomized clinical trial. JAMA 315:1844–1853CrossRefPubMed
2.
Zurück zum Zitat Strobel O, Berens V, Hinz U, et al. (2012) Resection after neoadjuvant therapy for locally advanced, “unresectable” pancreatic cancer. Surgery. 152(3 Suppl 1):S33–42CrossRefPubMed Strobel O, Berens V, Hinz U, et al. (2012) Resection after neoadjuvant therapy for locally advanced, “unresectable” pancreatic cancer. Surgery. 152(3 Suppl 1):S33–42CrossRefPubMed
3.
Zurück zum Zitat Kluger MD, Rashid MF, Rosario VL, Schrope BA, Steinman J, Hecht EM, Chabot JA. (2017) Resection of locally advanced pancreatic cancer without regression of arterial encasement after modern-era neoadjuvant therapy. J Gastrointest Surg. doi:10.1007/s11605-017-3556-1 PubMed Kluger MD, Rashid MF, Rosario VL, Schrope BA, Steinman J, Hecht EM, Chabot JA. (2017) Resection of locally advanced pancreatic cancer without regression of arterial encasement after modern-era neoadjuvant therapy. J Gastrointest Surg. doi:10.​1007/​s11605-017-3556-1 PubMed
4.
Zurück zum Zitat Ferrone CR, Marchegiani G, Hong TS, et al. (2015) Radiological and surgical implications of neoadjuvant treatment with FOLFIRINOX for locally advanced and borderline resectable pancreatic cancer. Ann Surg 261(1):12–17CrossRefPubMedPubMedCentral Ferrone CR, Marchegiani G, Hong TS, et al. (2015) Radiological and surgical implications of neoadjuvant treatment with FOLFIRINOX for locally advanced and borderline resectable pancreatic cancer. Ann Surg 261(1):12–17CrossRefPubMedPubMedCentral
5.
Zurück zum Zitat Pezzilli R, Serra C, Ricci C, et al. (2011) Radiofrequency ablation for advanced ductal pancreatic carcinoma: is this approach beneficial for our patients? A systematic review. Pancreas 40:163–165CrossRefPubMed Pezzilli R, Serra C, Ricci C, et al. (2011) Radiofrequency ablation for advanced ductal pancreatic carcinoma: is this approach beneficial for our patients? A systematic review. Pancreas 40:163–165CrossRefPubMed
6.
Zurück zum Zitat Varshney S, Sewkani A, Sharma S, et al. (2006) Radiofrequency ablation of unresectable pancreatic carcinoma: feasibility, efficacy and safety. JOP 7:74–78PubMed Varshney S, Sewkani A, Sharma S, et al. (2006) Radiofrequency ablation of unresectable pancreatic carcinoma: feasibility, efficacy and safety. JOP 7:74–78PubMed
7.
Zurück zum Zitat Rubinsky B (2007) Irreversible electroporation in medicine. Technol Cancer Res Treat 6(4):255–259CrossRefPubMed Rubinsky B (2007) Irreversible electroporation in medicine. Technol Cancer Res Treat 6(4):255–259CrossRefPubMed
8.
Zurück zum Zitat Martin RC 2nd, McFarland K, Ellis S, Velanovich V (2013) Irreversible electroporation in locally advanced pancreatic cancer: potential improved overall survival. Ann Surg Oncol 20(Suppl 3):S443–449CrossRefPubMed Martin RC 2nd, McFarland K, Ellis S, Velanovich V (2013) Irreversible electroporation in locally advanced pancreatic cancer: potential improved overall survival. Ann Surg Oncol 20(Suppl 3):S443–449CrossRefPubMed
9.
Zurück zum Zitat Martin RC 2nd, Durham AN, Besselink MG, et al. (2016) Irreversible electroporation in locally advanced pancreatic cancer: a call for standardization of energy delivery. J Surg Oncol 114:865–871CrossRefPubMed Martin RC 2nd, Durham AN, Besselink MG, et al. (2016) Irreversible electroporation in locally advanced pancreatic cancer: a call for standardization of energy delivery. J Surg Oncol 114:865–871CrossRefPubMed
10.
Zurück zum Zitat Philips P, Hays D, Martin RC (2013) Irreversible electroporation ablation (IRE) of unresectable soft tissue tumors: learning curve evaluation in the first 150 patients treated. PLoS ONE 8(11):e76260CrossRefPubMedPubMedCentral Philips P, Hays D, Martin RC (2013) Irreversible electroporation ablation (IRE) of unresectable soft tissue tumors: learning curve evaluation in the first 150 patients treated. PLoS ONE 8(11):e76260CrossRefPubMedPubMedCentral
11.
Zurück zum Zitat Ricke J, Jürgens JH, Deschamps F, et al. (2015) Irreversible electroporation (IRE) fails to demonstrate efficacy in a prospective multicenter phase II trial on lung malignancies: the ALICE trial. Cardiovasc Intervent Radiol 38:401–408CrossRefPubMed Ricke J, Jürgens JH, Deschamps F, et al. (2015) Irreversible electroporation (IRE) fails to demonstrate efficacy in a prospective multicenter phase II trial on lung malignancies: the ALICE trial. Cardiovasc Intervent Radiol 38:401–408CrossRefPubMed
12.
Zurück zum Zitat Bower M, Sherwood L, Li Y, Martin R (2011) Irreversible electroporation of the pancreas: definitive local therapy without systemic effects. J Surg Oncol 104(1):22–28CrossRefPubMed Bower M, Sherwood L, Li Y, Martin R (2011) Irreversible electroporation of the pancreas: definitive local therapy without systemic effects. J Surg Oncol 104(1):22–28CrossRefPubMed
13.
Zurück zum Zitat Martin RCG, Kwon D, Chalikonda S, et al. (2015) Treatment of 200 locally advanced (Stage III) pancreatic adenocarcinoma patients with irreversible electroporation. Ann Surg 262(3):486–494CrossRefPubMed Martin RCG, Kwon D, Chalikonda S, et al. (2015) Treatment of 200 locally advanced (Stage III) pancreatic adenocarcinoma patients with irreversible electroporation. Ann Surg 262(3):486–494CrossRefPubMed
14.
Zurück zum Zitat Dunki-Jacobs EM, Philips P, Martin RC (2014) Evaluation of resistance as a measure of successful tumor ablation during irreversible electroporation of the pancreas. J Am Coll Surg 218(2):179–187CrossRefPubMed Dunki-Jacobs EM, Philips P, Martin RC (2014) Evaluation of resistance as a measure of successful tumor ablation during irreversible electroporation of the pancreas. J Am Coll Surg 218(2):179–187CrossRefPubMed
15.
Zurück zum Zitat Olweny EO, Kapur P, Tan YK, et al. (2013) Irreversible electroporation: evaluation of nonthermal and thermal ablative capabilities in the porcine kidney. Urology 81(3):679–684CrossRefPubMed Olweny EO, Kapur P, Tan YK, et al. (2013) Irreversible electroporation: evaluation of nonthermal and thermal ablative capabilities in the porcine kidney. Urology 81(3):679–684CrossRefPubMed
16.
Zurück zum Zitat Faroja M, Ahmed M, Appelbaum L, et al. (2013) Irreversible electroporation ablation: is all the damage nonthermal? Radiology 266(2):462–470CrossRefPubMed Faroja M, Ahmed M, Appelbaum L, et al. (2013) Irreversible electroporation ablation: is all the damage nonthermal? Radiology 266(2):462–470CrossRefPubMed
17.
Zurück zum Zitat Dunki-Jacobs EM, Philips P, Ii RCGM (2014) Evaluation of thermal injury to liver, pancreas and kidney during irreversible electroporation in an in vivo experimental model. Br J Surg 101(9):1113–1121CrossRefPubMed Dunki-Jacobs EM, Philips P, Ii RCGM (2014) Evaluation of thermal injury to liver, pancreas and kidney during irreversible electroporation in an in vivo experimental model. Br J Surg 101(9):1113–1121CrossRefPubMed
18.
Zurück zum Zitat Charpentier KP, Wolf F, Noble L, et al. (2010) Irreversible electroporation of the pancreas in swine: a pilot study. HPB (Oxford). 12(5):348–351CrossRefPubMedPubMedCentral Charpentier KP, Wolf F, Noble L, et al. (2010) Irreversible electroporation of the pancreas in swine: a pilot study. HPB (Oxford). 12(5):348–351CrossRefPubMedPubMedCentral
19.
Zurück zum Zitat Fritz S, Sommer CM, Vollherbst D, et al. (2015) Irreversible electroporation of the pancreas is feasible and safe in a porcine survival model. Pancreas 44(5):791–798CrossRefPubMed Fritz S, Sommer CM, Vollherbst D, et al. (2015) Irreversible electroporation of the pancreas is feasible and safe in a porcine survival model. Pancreas 44(5):791–798CrossRefPubMed
20.
Zurück zum Zitat Wimmer T, Srimathveeravalli G, Gutta N, et al. (2013) Comparison of simulation-based treatment planning with imaging and pathology outcomes for percutaneous CT-guided irreversible electroporation of the porcine pancreas: a pilot study. J Vasc Interv Radiol 24(11):1709–1718CrossRefPubMed Wimmer T, Srimathveeravalli G, Gutta N, et al. (2013) Comparison of simulation-based treatment planning with imaging and pathology outcomes for percutaneous CT-guided irreversible electroporation of the porcine pancreas: a pilot study. J Vasc Interv Radiol 24(11):1709–1718CrossRefPubMed
21.
Zurück zum Zitat Zhang Z, Li W, Procissi D, et al. (2014) Rapid dramatic alterations to the tumor microstructure in pancreatic cancer following irreversible electroporation ablation. Nanomedicine. 9(8):1181–1192CrossRefPubMed Zhang Z, Li W, Procissi D, et al. (2014) Rapid dramatic alterations to the tumor microstructure in pancreatic cancer following irreversible electroporation ablation. Nanomedicine. 9(8):1181–1192CrossRefPubMed
22.
Zurück zum Zitat José A, Sobrevals L, Ivorra A, Fillat C (2012) Irreversible electroporation shows efficacy against pancreatic carcinoma without systemic toxicity in mouse models. Cancer Lett 317(1):16–23CrossRefPubMed José A, Sobrevals L, Ivorra A, Fillat C (2012) Irreversible electroporation shows efficacy against pancreatic carcinoma without systemic toxicity in mouse models. Cancer Lett 317(1):16–23CrossRefPubMed
23.
Zurück zum Zitat Al-Hawary MM, Francis IR, Chari ST, et al. (2014) Pancreatic ductal adenocarcinoma radiology reporting template: consensus statement of the Society of Abdominal Radiology and the American Pancreatic Association. Radiology 270(1):248–260CrossRefPubMed Al-Hawary MM, Francis IR, Chari ST, et al. (2014) Pancreatic ductal adenocarcinoma radiology reporting template: consensus statement of the Society of Abdominal Radiology and the American Pancreatic Association. Radiology 270(1):248–260CrossRefPubMed
24.
Zurück zum Zitat Schulz B, Ou J, Meter TV, Martin RCG (2016) Early nontumorous CT findings after irreversible electroporation of locally advanced pancreatic cancer. Abdom Radiol. 41(11):2142–2149CrossRef Schulz B, Ou J, Meter TV, Martin RCG (2016) Early nontumorous CT findings after irreversible electroporation of locally advanced pancreatic cancer. Abdom Radiol. 41(11):2142–2149CrossRef
25.
Zurück zum Zitat Gonzalez-Beicos A, Venkat S, Songrug T, et al. (2015) Irreversible electroporation of hepatic and pancreatic malignancies: radiologic-pathologic correlation. Tech Vasc Interv Radiol. 18(3):176–182CrossRefPubMed Gonzalez-Beicos A, Venkat S, Songrug T, et al. (2015) Irreversible electroporation of hepatic and pancreatic malignancies: radiologic-pathologic correlation. Tech Vasc Interv Radiol. 18(3):176–182CrossRefPubMed
26.
Zurück zum Zitat Akinwande O, Ahmad SS, Van Meter T, Schulz B, Martin RC (2015) CT findings of patients treated with irreversible electroporation for locally advanced pancreatic cancer. J Oncol. 2015:680319CrossRefPubMedPubMedCentral Akinwande O, Ahmad SS, Van Meter T, Schulz B, Martin RC (2015) CT findings of patients treated with irreversible electroporation for locally advanced pancreatic cancer. J Oncol. 2015:680319CrossRefPubMedPubMedCentral
27.
Zurück zum Zitat Vroomen LGPH, Scheffer HJ, Melenhorst MCAM, et al. (2017) MR and CT imaging characteristics and ablation zone volumetry of locally advanced pancreatic cancer treated with irreversible electroporation. Eur Radiol 27(6):2521–2531CrossRefPubMed Vroomen LGPH, Scheffer HJ, Melenhorst MCAM, et al. (2017) MR and CT imaging characteristics and ablation zone volumetry of locally advanced pancreatic cancer treated with irreversible electroporation. Eur Radiol 27(6):2521–2531CrossRefPubMed
28.
Zurück zum Zitat Yeh R, Steinman J, Luk L, Kluger MD, Hecht EM (2017) Imaging of pancreatic cancer: what the surgeon wants to know. Clin Imaging 42:203–217 Yeh R, Steinman J, Luk L, Kluger MD, Hecht EM (2017) Imaging of pancreatic cancer: what the surgeon wants to know. Clin Imaging 42:203–217
29.
Zurück zum Zitat Kwon D, Mcfarland K, Velanovich V, Martin RC (2014) Borderline and locally advanced pancreatic adenocarcinoma margin accentuation with intraoperative irreversible electroporation. Surgery. 156(4):910–922CrossRefPubMed Kwon D, Mcfarland K, Velanovich V, Martin RC (2014) Borderline and locally advanced pancreatic adenocarcinoma margin accentuation with intraoperative irreversible electroporation. Surgery. 156(4):910–922CrossRefPubMed
30.
Zurück zum Zitat Kluger MD, Epelboym I, Schrope BA, et al. (2015) Single-institution experience with irreversible electroporation for T4 pancreatic cancer: first 50 patients. Ann Surg Oncol 23(5):1736–1743CrossRefPubMed Kluger MD, Epelboym I, Schrope BA, et al. (2015) Single-institution experience with irreversible electroporation for T4 pancreatic cancer: first 50 patients. Ann Surg Oncol 23(5):1736–1743CrossRefPubMed
31.
Zurück zum Zitat Lambert L, Horejs J, Krska Z, et al. (2016) Treatment of locally advanced pancreatic cancer by percutaneous and intraoperative irreversible electroporation: general hospital cancer center experience. Neoplasma Lambert L, Horejs J, Krska Z, et al. (2016) Treatment of locally advanced pancreatic cancer by percutaneous and intraoperative irreversible electroporation: general hospital cancer center experience. Neoplasma
32.
Zurück zum Zitat Narayanan G, Hosein PJ, Beulaygue IC, et al. (2017) Percutaneous image-guided irreversible electroporation for the treatment of unresectable, locally advanced pancreatic adenocarcinoma. J Vasc Interv Radiol 28(3):342–348CrossRefPubMed Narayanan G, Hosein PJ, Beulaygue IC, et al. (2017) Percutaneous image-guided irreversible electroporation for the treatment of unresectable, locally advanced pancreatic adenocarcinoma. J Vasc Interv Radiol 28(3):342–348CrossRefPubMed
33.
Zurück zum Zitat Månsson C, Brahmstaedt R, Nilsson A, Nygren P, Karlson B-M (2016) Percutaneous irreversible electroporation for treatment of locally advanced pancreatic cancer following chemotherapy or radiochemotherapy. Eur J Surg Oncol (EJSO). 42(9):1401–1406CrossRefPubMed Månsson C, Brahmstaedt R, Nilsson A, Nygren P, Karlson B-M (2016) Percutaneous irreversible electroporation for treatment of locally advanced pancreatic cancer following chemotherapy or radiochemotherapy. Eur J Surg Oncol (EJSO). 42(9):1401–1406CrossRefPubMed
34.
Zurück zum Zitat Belfiore MP, Ronza FM, Romano F, et al. (2015) Percutaneous CT-guided irreversible electroporation followed by chemotherapy as a novel neoadjuvant protocol in locally advanced pancreatic cancer: our preliminary experience. Int J Surg. 21:34–39CrossRef Belfiore MP, Ronza FM, Romano F, et al. (2015) Percutaneous CT-guided irreversible electroporation followed by chemotherapy as a novel neoadjuvant protocol in locally advanced pancreatic cancer: our preliminary experience. Int J Surg. 21:34–39CrossRef
35.
Zurück zum Zitat Scheffer HJ, Vroomen LGPH, Jong MCD, et al. (2017) Ablation of locally advanced pancreatic cancer with percutaneous irreversible electroporation: results of the phase I/II PANFIRE study. Radiology 282(2):585–597CrossRefPubMed Scheffer HJ, Vroomen LGPH, Jong MCD, et al. (2017) Ablation of locally advanced pancreatic cancer with percutaneous irreversible electroporation: results of the phase I/II PANFIRE study. Radiology 282(2):585–597CrossRefPubMed
36.
Zurück zum Zitat Cannon R, Ellis S, Hayes D, Narayanan G, Martin RC (2012) Safety and early efficacy of irreversible electroporation for hepatic tumors in proximity to vital structures. J Surg Oncol 107(5):544–549CrossRefPubMed Cannon R, Ellis S, Hayes D, Narayanan G, Martin RC (2012) Safety and early efficacy of irreversible electroporation for hepatic tumors in proximity to vital structures. J Surg Oncol 107(5):544–549CrossRefPubMed
Metadaten
Titel
Irreversible electroporation of pancreatic adenocarcinoma: a primer for the radiologist
verfasst von
M. Farzan Rashid
Elizabeth M. Hecht
Jonathan A. Steinman
Michael D. Kluger
Publikationsdatum
19.10.2017
Verlag
Springer US
Erschienen in
Abdominal Radiology / Ausgabe 2/2018
Print ISSN: 2366-004X
Elektronische ISSN: 2366-0058
DOI
https://doi.org/10.1007/s00261-017-1349-3

Weitere Artikel der Ausgabe 2/2018

Abdominal Radiology 2/2018 Zur Ausgabe

Update Radiologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.